FDA grants priority review designation for Eisai’s Lenvatinib to treat advanced thyroid cancer
Discovered and developed by Eisai, lenvatinib is an oral multiple receptor tyrosine kinase inhibitor with a unique binding mode that selectively inhibits the kinase activities of vascular endothelial
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.